Clover Health

UBS raised its price target on Clover Health to $4.75 from $2.75 while keeping a Neutral rating, citing improved confidence in the company's operating outlook and profitability initiatives. Canaccord also lifted its target to $4.20 and reiterated a Buy rating after strong operating performance in April and May. Analysts point to a favorable managed-care environment and projected five-year EPS growth of 51.31% as drivers of growing optimism for Clover Health. » Plus sur finance.yahoo.com

On May 18, 2026 Dr. Carladenise Armbrister Edwards reported a direct open-market sale of 67,160 Clover Health Investments shares for about $230,000 at a weighted average price of $3.42, reducing her direct holdings by 19.05% to 285,432 shares. The sale occurred after strong Q1 results but before the stock later climbed to a 52-week high of $5.49 following a favorable court ruling that could unlock additional Medicare revenue. Edwards' remaining sizeable stake and absence of further sales suggest she maintains confidence in the company's outlook. » Plus sur finance.yahoo.com

Clover Health, a technology-powered provider of Medicare Advantage plans, raised its revenue forecast for the year to $2.81–$2.92 billion after strong results. Its core software, Clover Assistant, delivers real-time, AI-based recommendations to physicians, improving diagnoses and reducing treatment costs. The outlook and the AI features drove a sharp jump in the stock on June 10. » Plus sur finanzen.net